[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA32031B1 - Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf - Google Patents

Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf

Info

Publication number
MA32031B1
MA32031B1 MA33039A MA33039A MA32031B1 MA 32031 B1 MA32031 B1 MA 32031B1 MA 33039 A MA33039 A MA 33039A MA 33039 A MA33039 A MA 33039A MA 32031 B1 MA32031 B1 MA 32031B1
Authority
MA
Morocco
Prior art keywords
compositions
polypeptides
cclothoff
built
processes
Prior art date
Application number
MA33039A
Other languages
Arabic (ar)
English (en)
Inventor
David Glass
Shou-Ih Hu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32031B1 publication Critical patent/MA32031B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

L'invention concerne des procédés, des trousses et des compositions destinés à prévenir ou traiter des états ou troubles métaboliques liés à l'âge. L'invention porte sur des polypeptides de fusion klotho qui comprennent au moins une protéine klotho ou un fragment actif de cette dernière. Les protéines de fusion klotho précitées sont utilisées pour traiter et prévenir une variété d'états et de troubles métaboliques liés à l'âge.
MA33039A 2008-01-28 2010-07-19 Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf MA32031B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6301508P 2008-01-28 2008-01-28
PCT/EP2009/050850 WO2009095372A1 (fr) 2008-01-28 2009-01-26 Procédés et compositions faisant appel à des polypeptides de fusion klotho-fgf

Publications (1)

Publication Number Publication Date
MA32031B1 true MA32031B1 (fr) 2011-01-03

Family

ID=40492768

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33039A MA32031B1 (fr) 2008-01-28 2010-07-19 Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf

Country Status (21)

Country Link
US (2) US8481031B2 (fr)
EP (1) EP2247614B1 (fr)
JP (1) JP5627469B2 (fr)
KR (1) KR20100118126A (fr)
CN (1) CN102015760B (fr)
AR (1) AR070690A1 (fr)
AU (1) AU2009209696B2 (fr)
BR (1) BRPI0906722A2 (fr)
CA (2) CA2854933A1 (fr)
CL (1) CL2009000166A1 (fr)
CO (1) CO6300826A2 (fr)
CR (1) CR11580A (fr)
EA (1) EA201001204A1 (fr)
EC (1) ECSP10010372A (fr)
ES (1) ES2479417T3 (fr)
IL (1) IL207161A0 (fr)
MA (1) MA32031B1 (fr)
MX (1) MX2010008206A (fr)
PE (1) PE20091405A1 (fr)
TW (1) TW200936156A (fr)
WO (1) WO2009095372A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) * 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
AU2009302318A1 (en) 2008-10-10 2010-04-15 Amgen Inc. FGF21 mutants and uses thereof
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
WO2010129503A1 (fr) 2009-05-05 2010-11-11 Amgen Inc. Mutants de fgf21 et leurs utilisations
JP2012530493A (ja) * 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
KR101952453B1 (ko) * 2009-10-15 2019-02-26 제넨테크, 인크. 수용체 특이성이 변경된 키메라 섬유모세포 성장 인자
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
WO2011068893A1 (fr) * 2009-12-02 2011-06-09 Amgen Inc. Protéines de liaison qui se lient au fgfr1c humain, au β-klotho humain et à la fois au fgfr1c humain et au β-klotho humain
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
JP2013514366A (ja) 2009-12-16 2013-04-25 イーライ リリー アンド カンパニー 可溶性α−ＫＬＯＴＨＯの治療的使用
CA2796055A1 (fr) 2010-04-15 2011-10-20 Amgen Inc. Proteines de liaison au recepteur de fgf humain et a ?-klotho
ES2691642T3 (es) * 2010-05-21 2018-11-28 Xl-Protein Gmbh Polipéptidos de enrollamiento al azar de prolina/alanina biosintéticos y sus usos
PE20130648A1 (es) * 2010-06-25 2013-07-03 Shire Human Genetic Therapies Tratamiento del sindrome de sanfilippo tipo b
CN102465182A (zh) * 2010-10-29 2012-05-23 株式会社爱茉莉太平洋 检测皮肤活性物质的检测试剂盒和检测皮肤活性物质的方法
PE20141727A1 (es) 2011-07-01 2014-11-26 Ngm Biopharmaceuticals Inc Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
WO2013027191A1 (fr) * 2011-08-25 2013-02-28 Novartis Ag Procédés et compositions utilisant des polypeptides de fusion fgf23
TWI478002B (zh) * 2012-02-09 2015-03-21 Univ Nat Sun Yat Sen 一種篩選治療或預防帕金森氏症及其併發症之候選藥物的方法
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP4083221A1 (fr) 2012-12-27 2022-11-02 NGM Biopharmaceuticals, Inc. Peptides chimériques fgf19 pour l'utilisation dans le traitement de maladies de l'acide biliaire
WO2015060430A1 (fr) * 2013-10-24 2015-04-30 地方独立行政法人東京都健康長寿医療センター Cellules souche musculaires ou myoblastes, procédé pour la recherche par criblage de substances qui participent à une conversion métabolique l'utilisant et composition pharmaceutique comprenant une substance obtenue à partir dudit procédé de recherche par criblage
JP6560202B2 (ja) 2013-10-28 2019-08-21 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 癌モデル及び関連方法
EP3738981A1 (fr) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Anticorps liant beta-klotho 2 et leurs procédés d'utilisation
WO2015149069A1 (fr) * 2014-03-28 2015-10-01 New York University Protéines de fusion fgf23
WO2015183890A2 (fr) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Méthodes et compositions pour le traitement de maladies et de troubles métaboliques
WO2015195509A2 (fr) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
BR112017011398A2 (pt) * 2014-12-04 2018-04-03 Novartis Ag métodos e composições que usam polipeptídeos variantes de klotho
CN105838661B (zh) * 2014-12-30 2020-11-10 深圳市第二人民医院 Klotho基因编辑在异种肾脏移植中的应用
JP6794363B2 (ja) 2015-02-06 2020-12-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 認知の向上のための方法および組成物
EP3262159B1 (fr) * 2015-02-27 2019-07-24 Apceth GmbH & Co. KG Cellule souche mésenchymateuse génétiquement modifiée exprimant klotho
WO2017008016A1 (fr) * 2015-07-09 2017-01-12 The Board Of Regents Of The University Of Texas System Nanoparticules contenant une matrice extracellulaire pour l'administration de médicaments
WO2017019957A2 (fr) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Protéines de liaison et leurs procédés d'utilisation
EP3377090B1 (fr) 2015-11-09 2021-04-07 NGM Biopharmaceuticals, Inc. Méthodes de traitement de troubles associés aux acides biliaires
WO2019113373A2 (fr) * 2017-12-06 2019-06-13 Klotho Therapeutics, Inc. Produits et procédés d'évaluation et d'augmentation des taux de protéine klotho
CN116478907A (zh) * 2016-06-02 2023-07-25 克洛索治疗有限公司 治疗性重组klotho蛋白及其组合物和方法
CA3034399A1 (fr) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methodes de traitement de cancers et de tumeurs a mediation assuree par le facteur de croissance des fibroblastes 19
KR20190088988A (ko) * 2016-11-22 2019-07-29 클로토 테라퓨틱스, 아이엔씨. 신규한 재조합 클로토 단백질 및 이를 수반하는 조성물 및 방법
US11365228B2 (en) 2017-07-06 2022-06-21 Yale University Mutant FGF21 polypeptide compositions
JP2021506792A (ja) * 2017-12-13 2021-02-22 イエール ユニバーシティ 内分泌型ｆｇｆ２３関連疾患を処置または防止するための組成物および方法
CN108434441A (zh) * 2018-04-17 2018-08-24 哈尔滨博翱生物医药技术开发有限公司 新型成纤维细胞生长因子-21类似物在治疗弥漫性间质性肺脏疾病中的应用
CN109722480B (zh) * 2018-05-17 2022-04-26 上海交通大学 一种非小细胞肺癌检测试剂盒及其应用
WO2019236603A1 (fr) 2018-06-08 2019-12-12 Saint Louis University Procédés et compositions pour traiter une réduction de capacité cognitive
KR20220119056A (ko) * 2019-12-05 2022-08-26 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 골관절염 치료 방법
EP3879271A1 (fr) * 2020-03-10 2021-09-15 SALION GmbH Détection de klotho
US11891615B2 (en) 2020-06-10 2024-02-06 Gail Marion Humble Process to produce Klotho protein in vitro
US20220008519A1 (en) * 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US853A (en) 1838-07-24 Jesse reed
US6406A (en) 1849-05-01 Artificial teeth
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
WO1991006287A1 (fr) 1989-11-06 1991-05-16 Enzytech, Inc. Microspheres de proteines et leurs procedes d'utilisation
WO1991019810A1 (fr) 1990-06-15 1991-12-26 California Biotechnology Inc. Mammifere transgenique non humain presentant la pathologie de formation d'amyloides de la maladie d'alzheimer
US5408038A (en) * 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5541094A (en) 1992-09-25 1996-07-30 E. I. Du Pont De Nemours And Company Glyoxylic acid/aminomethylphosphonic acid mixtures prepared using a microbial transformant
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US6187992B1 (en) 1994-12-05 2001-02-13 Merck & Co., Inc. Transgenic mouse having a disrupted amyloid precursor protein gene
EP0850051A2 (fr) 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition se pretant a la liberation prolongee d'un agent
US6194177B1 (en) 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. DNA encoding a hybrid heterodimeric protein
US6239181B1 (en) 1996-03-15 2001-05-29 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neurophathy by administering selegiline
US6358752B1 (en) 1996-09-27 2002-03-19 Cornell Research Foundation, Inc. Liposome-enhanced test device and method
JP4112627B2 (ja) 1996-12-26 2008-07-02 社団法人芝蘭会 新規ポリペプチド、新規ｄｎａおよび新規抗体
US6127598A (en) 1997-07-25 2000-10-03 The Regents Of The University Of California NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6537749B2 (en) 1998-04-03 2003-03-25 Phylos, Inc. Addressable protein arrays
US7060479B2 (en) 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
ES2256000T3 (es) 1999-04-22 2006-07-16 Liposcience, Inc. Procedimiento de rmn para determinar el riesgo de desarrollar diabetes tipo 2.
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
WO2001066595A2 (fr) 2000-03-08 2001-09-13 Chiron Corporation Gene humain fgf-23 et produits d'expression associes
US7223563B2 (en) 2000-07-19 2007-05-29 Advanced Research And Technology Institute Fibroblast growth factor (FGF23) nucleic acids
JP2004524024A (ja) 2001-01-30 2004-08-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規の核酸およびポリペプチド分子
US7588757B2 (en) 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
JP2006240990A (ja) * 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
CA2545539A1 (fr) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Modification de demi-vies seriques de proteines de fusion fc par mutagenese de positions 250, 314 et/ou 428 de la region constante de la chaine lourde des immunoglobulines
JP2006158339A (ja) * 2004-12-09 2006-06-22 Kyoto Univ βＫｌｏｔｈｏ遺伝子、Ｃｙｐ７ａ１遺伝子、及びそれらの利用
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
WO2009117622A2 (fr) 2008-03-19 2009-09-24 Ambrx, Inc. Polypeptides fgf-23 modifiés et leurs utilisations
AU2009302318A1 (en) 2008-10-10 2010-04-15 Amgen Inc. FGF21 mutants and uses thereof
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules

Also Published As

Publication number Publication date
PE20091405A1 (es) 2009-10-07
US8481031B2 (en) 2013-07-09
AU2009209696A1 (en) 2009-08-06
EP2247614A1 (fr) 2010-11-10
JP5627469B2 (ja) 2014-11-19
BRPI0906722A2 (pt) 2015-07-07
ECSP10010372A (es) 2010-08-31
CO6300826A2 (es) 2011-07-21
EP2247614B1 (fr) 2014-04-09
CA2712634A1 (fr) 2009-08-06
AR070690A1 (es) 2010-04-28
US20090192087A1 (en) 2009-07-30
TW200936156A (en) 2009-09-01
US9458209B2 (en) 2016-10-04
CA2712634C (fr) 2014-09-16
CA2854933A1 (fr) 2009-08-06
KR20100118126A (ko) 2010-11-04
AU2009209696B2 (en) 2012-04-19
CN102015760A (zh) 2011-04-13
MX2010008206A (es) 2010-08-10
EA201001204A1 (ru) 2011-02-28
CL2009000166A1 (es) 2010-12-24
JP2011510620A (ja) 2011-04-07
WO2009095372A1 (fr) 2009-08-06
IL207161A0 (en) 2010-12-30
ES2479417T3 (es) 2014-07-24
CN102015760B (zh) 2014-06-11
CR11580A (es) 2010-10-05
US20130324458A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
MA32031B1 (fr) Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MY149630A (en) Antibodies against amyloid-beta peptide
WO2007141796A3 (fr) Utilisations thérapeutiques d'inhibiteurs de rtp801l
WO2006096487A3 (fr) Methodes et compositions de modulation de l'activite de tweak et de fn14
WO2008021210A3 (fr) Méthodes et compositions pour le traitement de troubles neurodégénératifs
NO20063986L (no) Anti-CD-38-humane antistoffer og anvendelse derav
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA200700136A1 (ru) Анти-cd154-антитела
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
UA108066C2 (uk) Білки, що зв'язуються з cgrp-рецепторами людини
TW200806325A (en) Therapeutic uses of inhibitors of RTP801
MA34053B1 (fr) Polypeptides agonistes de liaison à dr5
ATE469895T1 (de) Cgrp-rezeptorantagonisten
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
EP2279244A4 (fr) Procédés et compositions pour l 'administration orale de protéines
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon